Skip to content

Agios Fellowship Program

Agios, in collaboration with MCPHS University, offers a unique fellowship program to promote the role of the Doctor of Pharmacy (PharmD) within the biopharmaceutical industry. A fellow gains extensive experiences through various practical activities in both industry and academic settings, which could enhance the potential for accelerated career development. This year Agios is recruiting for a 2022-2024 Health Economics & Outcome Research fellow. Below are the current fellowship programs: 

  • Health Economics & Outcomes Research (New Program, recruiting for a 2022-2024 fellow)
  • Medical Safety & Risk Management
  • Clinical Supply Chain
  • Regulatory Affairs – Clinical Strategy
  • Regulatory Affairs – Chemistry, Manufacturing, and Controls

Fellowship Overview

This fellowship program is designed to offer Doctor of Pharmacy graduates in-depth experience within a biopharmaceutical industry setting. In addition, PharmD graduates will have the opportunity to enhance their clinical and academic background in conjunction with MCPHS University. Overall, this fellowship program will provide the training and experiences necessary to prepare the fellow for a career in the competitive pharmaceutical industry.

Please see our brochure for additional details and feel free to review the content below.

About Agios

Agios is a biopharmaceutical company passionately committed to applying scientific leadership in the field of cellular metabolism to transform the lives of patients with genetically defined diseases. Metabolism is a complex biological process involving the uptake and assimilation of nutrients in cells to produce energy and facilitate many of the processes required for cellular division and growth. Agios believes that dysregulation of normal cellular metabolism plays a crucial role in many genetic diseases. We believe Agios is a first mover in using cellular metabolism, an unexploited area of biological research with disruptive potential, as a platform for developing potentially transformative medicines. Agios intends to apply a deep understanding of metabolism, coupled with the ability to create medicines that can inhibit or activate metabolic enzymes, to fundamentally change the way genetically defined diseases are treated.

Agios has a dynamic culture, which supports our employees’ unwavering commitment to science and patients. World-class founding and leadership teams with the experience and track record to provide the insights required to develop groundbreaking medicines lead a group of exceptional employees.

We pride ourselves on fostering an interconnected environment that encourages creative scientific collaboration across disciplines. Our unique culture, combined with the commitment and passion of our team, reflect our belief in an “other side of possible” approach to our challenges and our work.

About Health Economics & Outcomes Research

The Health Economics & Outcomes Research (HEOR) department at Agios is responsible for generating, interpreting, and communicating high quality, customer-centric medical evidence, supporting assets from early development through post-marketing, to demonstrate value and help ensure optimal access to Agios’ therapies. The HEOR team leads patient-centered research via the incorporation of clinical outcomes assessments within trials, evidence generation (real-world evidence, observational studies, systematic literature reviews, etc.), health economics (cost-effectiveness models, budget impact models), and value demonstration. These activities serve to highlight the unmet need and communicate value to key stakeholders including patients, health care providers, payers, and regulatory bodies. As an integral part of drug development and commercialization, the HEOR group continuously collaborates cross-functionally to ensure alignment of strategy across teams.

Fellowship Goals and Objectives

The goal of the Agios HEOR Fellowship Program is to equip the fellow with technical skills and provide opportunities for real-world application of HEOR in the pharmaceutical industry.

Objectives include:

  1. To provide training and experience in the areas of health economics, outcomes research, and market access.
  2. To enhance the fellow’s technical expertise in literature evaluation, epidemiology, research methodology, value communication, and biostatistics.
  3. To provide experience contributing to research and development of investigational products with a focus on clinical outcomes assessments.

Program Design

As an integrated member of the HEOR team at Agios, the fellow will achieve a deeper understanding of the complexities surrounding cost and access of pharmaceuticals within the genetically-defined disease portfolio, including pyruvate kinase deficiency, thalassemia, and sickle cell disease. Over two years, the fellow will gain proficiency in the analytical methods required to evaluate pharmaceutical products and communicate their value to patients and other stakeholders within the healthcare system.

Agios offers experienced leadership to guide the fellow in key areas of HEOR to become a well-rounded researcher and strategist. Activities and responsibilities over the two years may include and are not limited to the following:

Year 1

  • Integrate into the HEOR and relevant cross-functional teams by collaborating regularly with Clinical Development, Medical Affairs, Market Access, Marketing, and Regulatory
  • Learn to demonstrate value by contributing to development of value dossiers (AMCP dossier, Global value dossier)
  • Develop skills in health economics by contributing to budget impact models, burden of illness models, and cost-effectiveness models
  • Conduct HTA surveillance, systematic literature reviews and other evidence generation activities

Year 2

  • Gain experience in patient-centered research and improve understanding of clinical outcomes assessments and their role in drug development and commercialization
  • Conduct data analyses for trial and observational studies
  • Become proficient in generating real-world evidence (cohort studies, claims analyses, indirect treatment comparisons, etc.) using advanced outcomes research methodology

For more information or questions, please contact:
Erin Zagadailov